Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06092047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 16, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2023 to Oct 1, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2023 to Oct 1, 2023
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.
Trial Details
NCT Number NCT06092047
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators: Anhui Provincial Hospital
Conditions CD19-positive Relapsed or Refractory B-cell Malignancies
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov